BioLineRx (BLRX) Reports FY 21 Net Loss of $27.1M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update
March 16, 2022 7:00 AM EDTTEL AVIV, Israel, March 16, 2022 /PRNewswire/ --Â BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the fourth quarter and year ended December 31, 2021 and provides a corporate update.
Significant events and achievements during the fourth quarter 2021 and subsequent period:
Commissioned a comprehensive third-party market assessment of the US stem cell mobilization market, which identified a commercial opportunity in the US of ~$360 million; Completed a successful... More